Vicore Pharma Holding AB (publ)

SSE:VICO.ST

14.38 (SEK) • At close February 20, 2024
Bedrijfsnaam Vicore Pharma Holding AB (publ)
Symbool VICO.ST
Munteenheid SEK
Prijs 14.38
Beurswaarde 1,606,576,740
Dividendpercentage 0%
52-weken bereik 12.36 - 26.9
Industrie Biotechnology
Sector Healthcare
CEO Mr. Ahmed S. Mousa J.D.
Website https://www.vicorepharma.com

An error occurred while fetching data.

Over Vicore Pharma Holding AB (publ)

Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis

Vergelijkbare Aandelen

RaySearch Laboratories AB (publ) logo

RaySearch Laboratories AB (publ)

RAY-B.ST

92.2 SEK

Intervacc AB (publ) logo

Intervacc AB (publ)

IVACC.ST

3.735 SEK

IRLAB Therapeutics AB (publ) logo

IRLAB Therapeutics AB (publ)

IRLAB-A.ST

14.45 SEK

Doxa AB (publ) logo

Doxa AB (publ)

DOXA.ST

3.2 SEK

Elos Medtech AB (publ) logo

Elos Medtech AB (publ)

ELOS-B.ST

203 SEK

Humana AB (publ) logo

Humana AB (publ)

HUM.ST

27 SEK

Mentice AB (publ) logo

Mentice AB (publ)

MNTC.ST

34.4 SEK

Xbrane Biopharma AB (publ) logo

Xbrane Biopharma AB (publ)

XBRANE.ST

2.085 SEK

Q-linea AB (publ) logo

Q-linea AB (publ)

QLINEA.ST

2.49 SEK

Financiële Gegevens

Cijfers zijn in miljoenen (SEK)

Cijfers zijn in miljoenen (SEK)